These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 20431387

  • 1. Photosensitivity in immunocompromised patients receiving long-term therapy with oral voriconazole.
    Frick MA, Soler-Palacín P, Martín Nalda A, Guarner ME, Nadal CF.
    Pediatr Infect Dis J; 2010 May; 29(5):480-1. PubMed ID: 20431387
    [No Abstract] [Full Text] [Related]

  • 2. Idiosyncratic nature of voriconazole photosensitivity in children undergoing cancer therapy.
    Hansford JR, Cole C, Blyth CC, Gottardo NG.
    J Antimicrob Chemother; 2012 Jul; 67(7):1807-9. PubMed ID: 22454488
    [No Abstract] [Full Text] [Related]

  • 3. Utilisation, efficacy and safety of voriconazole: prospective, non-interventional study on treatment of IFIs in clinical practice.
    Heinz WJ, Silling G, Böhme A.
    Curr Med Res Opin; 2011 Feb; 27(2):335-42. PubMed ID: 21155707
    [Abstract] [Full Text] [Related]

  • 4. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
    Soler-Palacín P, Frick MA, Martín-Nalda A, Lanaspa M, Pou L, Roselló E, de Heredia CD, Figueras C.
    J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pseudoporphyria associated with voriconazole.
    Kwong WT, Hsu S.
    J Drugs Dermatol; 2007 Oct; 6(10):1042-4. PubMed ID: 17966183
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.
    Lutsar I, Roffey S, Troke P.
    Clin Infect Dis; 2003 Sep 01; 37(5):728-32. PubMed ID: 12942409
    [Abstract] [Full Text] [Related]

  • 9. Voriconazole-induced photosensitivity.
    Malani AN, Aronoff DM.
    Clin Med Res; 2008 Sep 01; 6(2):83-5. PubMed ID: 18801950
    [Abstract] [Full Text] [Related]

  • 10. Voriconazole-induced retinoid-like photosensitivity in children.
    Rubenstein M, Levy ML, Metry D.
    Pediatr Dermatol; 2004 Sep 01; 21(6):675-8. PubMed ID: 15575856
    [Abstract] [Full Text] [Related]

  • 11. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.
    den Hollander JG, van Arkel C, Rijnders BJ, Lugtenburg PJ, de Marie S, Levin MD.
    J Antimicrob Chemother; 2006 Jun 01; 57(6):1248-50. PubMed ID: 16556632
    [Abstract] [Full Text] [Related]

  • 12. Phototoxic dermatoses in pediatric BMT patients receiving voriconazole.
    Goyal RK, Gehris RP, Howrie D, Cogley KM, Windreich RM, Venkataramanan R.
    Pediatr Blood Cancer; 2014 Jul 01; 61(7):1325-8. PubMed ID: 24619922
    [Abstract] [Full Text] [Related]

  • 13. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
    Przepiorka D, Buadi FK, McClune B.
    Pharmacotherapy; 2008 Jan 01; 28(1):58-63. PubMed ID: 18154475
    [Abstract] [Full Text] [Related]

  • 14. Oral voriconazole dose in children: one size does not fit all.
    Goutelle S, Larcher R, Padoin C, Mialou V, Bleyzac N.
    Clin Infect Dis; 2010 Oct 01; 51(7):870; author reply 871. PubMed ID: 20809842
    [No Abstract] [Full Text] [Related]

  • 15. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age.
    Shima H, Miharu M, Osumi T, Takahashi T, Shimada H.
    Pediatr Blood Cancer; 2010 Jul 01; 54(7):1050-2. PubMed ID: 20146339
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
    Vehreschild JJ, Böhme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, Ullmann AJ, Mousset S, Hummel M, Frommolt P, Wassmer G, Drzisga I, Cornely OA.
    J Infect; 2007 Nov 01; 55(5):445-9. PubMed ID: 17822770
    [Abstract] [Full Text] [Related]

  • 18. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.
    Pieper S, Kolve H, Gumbinger HG, Goletz G, Würthwein G, Groll AH.
    J Antimicrob Chemother; 2012 Nov 01; 67(11):2717-24. PubMed ID: 22796890
    [Abstract] [Full Text] [Related]

  • 19. Editorial commentary: Antifungal therapeutic drug monitoring progress: getting it right the first time.
    Andes D, Lepak A.
    Clin Infect Dis; 2012 Aug 01; 55(3):391-3. PubMed ID: 22610924
    [No Abstract] [Full Text] [Related]

  • 20. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
    Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A.
    J Clin Pharmacol; 2002 Apr 01; 42(4):395-402. PubMed ID: 11936564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.